Aduhelm Approved for Alzheimer's Disease

Aduhelm (aducanumab), developed by Biogen and Eisai, was approved by the U.S. Food and Drug Administration in June 2021, making it the first disease-modifying therapy for the treatment of Alzheimer’s disease. It is designed to reduce the number of amyloid plaques present in the brain, potentially slowing neurodegeneration and disease progression. Learn more about this therapy and its path to approval below.

Learn more
Aduhelm approved

FDA Approves Aduhelm, First Targeted Alzheimer’s Therapy

For the first time in almost 18 years, the U.S. Food and Drug Administration (FDA) has approved a new treatment — Aduhelm, also known as aducanumab — for Alzheimer’s disease, and a first targeted treatment for patients. With this approval, Aduhelm…

Read more
top 10 | Alzheimer's News Today | illustration for top 10 news stories of the year

Top 10 Alzheimer’s Disease Stories of 2021

Alzheimer’s News Today brought you coverage of the latest scientific advances, developments in treatment, and clinical trials related to Alzheimer’s disease throughout 2021. We look forward to continuing to report important news for the Alzheimer’s community this year. Here are the…

Aduhelm data presented

#AAIC21 – Aduhelm Shows Range of Benefits in EMERGE

Treatment with Aduhelm (aducanumab) slows the clinical decline observed in in Alzheimer’s across a range of cognitive and functional measurements, according to a new analysis of data from a Phase 3 clinical trial. The results were presented at the Alzheimer’s Association…